# The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial

> **NCT03182634** · PHASE2 · UNKNOWN · sponsor: **Institute of Cancer Research, United Kingdom** · enrollment: 1150 (estimated)

## Conditions studied

- Advanced Breast Cancer

## Interventions

- **DRUG:** Fulvestrant
- **DRUG:** Neratinib
- **DRUG:** AZD5363
- **DRUG:** Olaparib
- **DRUG:** AZD6738

## Key facts

- **NCT ID:** NCT03182634
- **Lead sponsor:** Institute of Cancer Research, United Kingdom
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-12-15
- **Primary completion:** 2022-11
- **Final completion:** 2023-11
- **Target enrollment:** 1150 (ESTIMATED)
- **Last updated:** 2019-01-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03182634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03182634, "The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03182634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*